U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Unfavorable Hodgkin Lymphoma

MedGen UID:
384921
•Concept ID:
C2347992
•
Neoplastic Process

Definition

An advanced Hodgkin lymphoma with unfavorable prognosis. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Unfavorable Hodgkin Lymphoma

Professional guidelines

PubMed

Treatment approaches for older Hodgkin lymphoma patients.
Bröckelmann PJ
Curr Opin Oncol 2024 Sep 1;36(5):353-359. Epub 2024 Jun 20 doi: 10.1097/CCO.0000000000001071. PMID: 39005230
The treatment of older Hodgkin lymphoma patients.
Böll B, Görgen H
Br J Haematol 2019 Jan;184(1):82-92. Epub 2018 Nov 8 doi: 10.1111/bjh.15652. PMID: 30407626
Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.
Gonzalez VJ
Curr Hematol Malig Rep 2017 Jun;12(3):244-250. doi: 10.1007/s11899-017-0385-y. PMID: 28497317

Recent clinical studies

Etiology

Treatment approaches for older Hodgkin lymphoma patients.
Bröckelmann PJ
Curr Opin Oncol 2024 Sep 1;36(5):353-359. Epub 2024 Jun 20 doi: 10.1097/CCO.0000000000001071. PMID: 39005230
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N
Blood 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348. PMID: 37832030
Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma.
Hidman J, Larsson A, Thulin M, Karlsson T
Ups J Med Sci 2023;128 Epub 2023 May 9 doi: 10.48101/ujms.v128.9392. PMID: 37223632Free PMC Article
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291
Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A
Crit Rev Oncol Hematol 2013 Feb;85(2):216-37. Epub 2012 Aug 4 doi: 10.1016/j.critrevonc.2012.07.002. PMID: 22867814

Diagnosis

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N
Blood 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348. PMID: 37832030
The treatment of older Hodgkin lymphoma patients.
Böll B, Görgen H
Br J Haematol 2019 Jan;184(1):82-92. Epub 2018 Nov 8 doi: 10.1111/bjh.15652. PMID: 30407626
Hodgkin lymphoma in elderly patients.
Borchmann S, Engert A, Böll B
Curr Opin Oncol 2018 Sep;30(5):308-316. doi: 10.1097/CCO.0000000000000464. PMID: 29994901
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291
Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A
Crit Rev Oncol Hematol 2013 Feb;85(2):216-37. Epub 2012 Aug 4 doi: 10.1016/j.critrevonc.2012.07.002. PMID: 22867814

Therapy

Treatment approaches for older Hodgkin lymphoma patients.
Bröckelmann PJ
Curr Opin Oncol 2024 Sep 1;36(5):353-359. Epub 2024 Jun 20 doi: 10.1097/CCO.0000000000001071. PMID: 39005230
The treatment of older Hodgkin lymphoma patients.
Böll B, Görgen H
Br J Haematol 2019 Jan;184(1):82-92. Epub 2018 Nov 8 doi: 10.1111/bjh.15652. PMID: 30407626
Hodgkin lymphoma in elderly patients.
Borchmann S, Engert A, Böll B
Curr Opin Oncol 2018 Sep;30(5):308-316. doi: 10.1097/CCO.0000000000000464. PMID: 29994901
Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.
Gonzalez VJ
Curr Hematol Malig Rep 2017 Jun;12(3):244-250. doi: 10.1007/s11899-017-0385-y. PMID: 28497317
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291

Prognosis

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N
Blood 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348. PMID: 37832030
The treatment of older Hodgkin lymphoma patients.
Böll B, Görgen H
Br J Haematol 2019 Jan;184(1):82-92. Epub 2018 Nov 8 doi: 10.1111/bjh.15652. PMID: 30407626
SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP, Fanale MA, Bartlett NL
Clin Lymphoma Myeloma Leuk 2018 Feb;18(2):81-90. Epub 2018 Jan 4 doi: 10.1016/j.clml.2018.01.001. PMID: 29366607
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291
Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A
Crit Rev Oncol Hematol 2013 Feb;85(2):216-37. Epub 2012 Aug 4 doi: 10.1016/j.critrevonc.2012.07.002. PMID: 22867814

Clinical prediction guides

Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis.
Knauft J, Schenk T, Ernst T, Schnetzke U, Hochhaus A, La Rosée P, Birndt S
Leukemia 2024 Feb;38(2):235-249. Epub 2024 Jan 18 doi: 10.1038/s41375-024-02135-8. PMID: 38238443Free PMC Article
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
van Heek L, Weindler J, Gorniak C, Kaul H, Müller H, Mettler J, Baues C, Fuchs M, Borchmann P, Ferdinandus J, Dietlein M, Voltin CA, Kobe C, Roth KS
Eur J Haematol 2023 Dec;111(6):881-887. Epub 2023 Aug 29 doi: 10.1111/ejh.14093. PMID: 37644732
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Gerhard-Hartmann E, Goergen H, Bröckelmann PJ, Mottok A, Steinmüller T, Grund J, Zamò A, Ben-Neriah S, Sasse S, Borchmann S, Fuchs M, Borchmann P, Reinke S, Engert A, Veldman J, Diepstra A, Klapper W, Rosenwald A
Br J Haematol 2022 Jan;196(1):116-126. Epub 2021 Sep 14 doi: 10.1111/bjh.17793. PMID: 34520052
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B
Cochrane Database Syst Rev 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3. PMID: 28541603Free PMC Article
Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.
Zhu YJ, Sun YL, Xia Y, Jiang WQ, Huang JJ, Huang HQ, Lin TY, Guan ZZ, Li ZM
Med Oncol 2012 Jun;29(2):1127-33. Epub 2011 Mar 10 doi: 10.1007/s12032-011-9902-3. PMID: 21390515

Recent systematic reviews

Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis.
Travaglino A, Russo D, Varricchio S, Picardi M, Mascolo M
Pathol Res Pract 2021 Mar;219:153370. Epub 2021 Feb 8 doi: 10.1016/j.prp.2021.153370. PMID: 33618247
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B
Cochrane Database Syst Rev 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3. PMID: 28541603Free PMC Article
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N
Cochrane Database Syst Rev 2015 Jan 9;1(1):CD010533. doi: 10.1002/14651858.CD010533.pub2. PMID: 25572491Free PMC Article
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
Bauer K, Skoetz N, Monsef I, Engert A, Brillant C
Cochrane Database Syst Rev 2011 Aug 10;(8):CD007941. doi: 10.1002/14651858.CD007941.pub2. PMID: 21833963
Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, Nihashi T, Nagai H
J Clin Oncol 2009 Apr 10;27(11):1906-14. Epub 2009 Mar 9 doi: 10.1200/JCO.2008.16.0861. PMID: 19273713

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...